Cognitive and Cerebral Blood Flow Effects of Resveratrol
Conditions
Keywords
resveratrol, cerebral blood flow, NIRS, cognitive performance
Brief summary
Research shows that resveratrol is able to induce vasodilation (and therefore blood flow) by interacting with nitric oxide (NO). Research also shows that acute administration of metabolic substrates, like oxygen and glucose, can enhance aspects of cognitive performance in young, healthy humans. The aim of this investigation was to determine if the consumption of resveratrol could modulate cerebral blood flow and if this in turn could influence cognitive performance by increasing access to blood borne metabolic fuel. Results showed that compared to placebo, after consuming 500mg pure trans-resveratrol, levels of total haemoglobin were significantly higher in the frontal cortex of young, healthy participants during cognitive task completion. Cognitive performance was not effected.
Interventions
DIETARY_SUPPLEMENTTrans- resveratrol
All 24 participants who completed the study took part in 3 conditions; receiving either 250mg resveratrol, 500mg resveratrol or placebo on separate days (with a 48hr-14day wash out period between each treatment) with the order dictated by a latin square. Treatment was administered in capsule form and in a double blind manner.
OTHERPlacebo (silica)
All 24 participants who completed the study took part in 3 conditions; receiving either 250mg resveratrol, 500mg resveratrol or placebo on separate days (with a 48hr-14day wash out period between each treatment) with the order dictated by a latin square. Treatment was administered in capsule form and in a double blind manner.
Sponsors
Northumbria University
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 35 Years
Healthy volunteers
Yes
Inclusion criteria
* Male/female, * Healthy * Age 18-35 years old * Non smoker * Proficient in English * Not taking any herbal or prescription medications * Not pregnant * Does not drink more than 6 cups of coffee per day
Exclusion criteria
* Suffered a head injury, neurological disorder or neuro-developmental disorder * Food allergies/intolerances
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Modulation of Levels of Total Haemoglobin | 0-81 mins (absorption period=1- 45 mins , post dose period 46- 81 mins) | This outcome measure provides the change from baseline values (in µmol/L) of total levels of haemoglobin during the 46-81 min post dose testing period. This was measured in the frontal cortex by near infrared spectroscopy (NIRS). |
| Modulation of Deoxygenated Levels of Haemoglobin | 0-81 mins (absorption period=1- 45 mins , post dose period 46- 81 mins) | This outcome measure provides the change from baseline values (in µmol/L) of levels of deoxygenated haemoglobin during the 46-81 min post dose testing period. This was measured in the frontal cortex by near infrared spectroscopy (NIRS). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Significant Modulation of Cognitive Performance | 46-81 mins post dose | This outcome measure assessed any significant modulation of cognitive task performance during the 46-81 min post dose period. The cognitive tasks utilized were cognitively demanding computer based, numerical tasks which assessed working memory. Significant modulation is defined as significant difference between baseline and post-dose task performance. |
Countries
United Kingdom
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Resveratrol 250mg Then Resveratrol 500mg Then Placebo | 8 |
| Resveratrol 500mg Then Placebo Then Resveratrol 250mg | 8 |
| Placebo Then Resveratrol 250mg Then Resveratrol 500mg | 8 |
| Total | 24 |
Baseline characteristics
| Characteristic | Total | Resveratrol 250mg Then Resveratrol 500mg Then Placebo | Resveratrol 500mg Then Placebo Then Resveratrol 250mg | Placebo Then Resveratrol 250mg Then Resveratrol 500mg |
|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 24 Participants | 8 Participants | 8 Participants | 8 Participants |
| Age Continuous | 20 years STANDARD_DEVIATION 2 | 19.2 years STANDARD_DEVIATION 2.2 | 21.3 years STANDARD_DEVIATION 1.8 | 20 years STANDARD_DEVIATION 2 |
| Region of Enrollment United Kingdom | 24 participants | 8 participants | 8 participants | 8 participants |
| Sex: Female, Male Female | 20 Participants | 6 Participants | 7 Participants | 7 Participants |
| Sex: Female, Male Male | 4 Participants | 2 Participants | 1 Participants | 1 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — |
| other Total, other adverse events | 0 / 24 | 0 / 24 | 0 / 24 |
| serious Total, serious adverse events | 0 / 24 | 0 / 24 | 0 / 24 |
Outcome results
Primary
Modulation of Deoxygenated Levels of Haemoglobin
This outcome measure provides the change from baseline values (in µmol/L) of levels of deoxygenated haemoglobin during the 46-81 min post dose testing period. This was measured in the frontal cortex by near infrared spectroscopy (NIRS).
Time frame: 0-81 mins (absorption period=1- 45 mins , post dose period 46- 81 mins)
Population: NIRS data was analysed for all participants who completed the trial and who were not noted as having significantly high or low readings during data collection.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Resveratrol 250mg | Modulation of Deoxygenated Levels of Haemoglobin | 0.4 µmol/L | Standard Error 0.2 |
| Resveratrol 500mg | Modulation of Deoxygenated Levels of Haemoglobin | 0.2 µmol/L | Standard Error 0.11 |
| Placebo | Modulation of Deoxygenated Levels of Haemoglobin | -0.2 µmol/L | Standard Error 0.1 |
Comparison: An omnibus ANOVA was carried out with a priori planned comparisons using the mean squares error term from this ANOVA.p-value: <0.05ANOVA
Comparison: An omnibus ANOVA was carried out with a priori planned comparisons using the mean squares error term from this ANOVA.p-value: <0.05ANOVA
Primary
Modulation of Levels of Total Haemoglobin
This outcome measure provides the change from baseline values (in µmol/L) of total levels of haemoglobin during the 46-81 min post dose testing period. This was measured in the frontal cortex by near infrared spectroscopy (NIRS).
Time frame: 0-81 mins (absorption period=1- 45 mins , post dose period 46- 81 mins)
Population: NIRS data was analysed for all participants who completed the trial and who were not noted as having significantly high or low readings during data collection.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Resveratrol 250mg | Modulation of Levels of Total Haemoglobin | 1.9 µmol/L | Standard Error 0.9 |
| Resveratrol 500mg | Modulation of Levels of Total Haemoglobin | 2.4 µmol/L | Standard Error 0.8 |
| Placebo | Modulation of Levels of Total Haemoglobin | 1.2 µmol/L | Standard Error 0.1 |
Comparison: Data was analysed by omnibus ANOVA with a priori planned comparisons utilizing the mean squares error term from this ANOVA.p-value: >0.05ANOVA
Comparison: Data was analysed by omnibus ANOVA with a priori planned comparisons utilizing the mean squares error term from this ANOVA.p-value: <0.05ANOVA
Secondary
Number of Participants With Significant Modulation of Cognitive Performance
This outcome measure assessed any significant modulation of cognitive task performance during the 46-81 min post dose period. The cognitive tasks utilized were cognitively demanding computer based, numerical tasks which assessed working memory. Significant modulation is defined as significant difference between baseline and post-dose task performance.
Time frame: 46-81 mins post dose
Population: Cognitive performance data was analysed for all subjects who completed the trial. If data was not utilized in the final analysis then this was either due to technical issues (i.e. the computer did not save data) or it was clear that the participant had not engaged with the task/s.
| Arm | Measure | Value (NUMBER) | Dispersion |
|---|---|---|---|
| Resveratrol 250mg | Number of Participants With Significant Modulation of Cognitive Performance | 0 Participants | 0 |
| Resveratrol 500mg | Number of Participants With Significant Modulation of Cognitive Performance | 0 Participants | 0 |
| Placebo | Number of Participants With Significant Modulation of Cognitive Performance | 0 Participants | 0 |
Comparison: Performance on each cognitive task was assessed via omnibus ANOVA with a priori planned comparisons.p-value: >0.05ANOVA
Comparison: Performance on each cognitive task was assessed via omnibus ANOVA with a priori planned comparisons.p-value: >0.05ANOVA